Syndax Pharmaceuticals (NASDAQ:SNDX) is focused on developing therapies that could potentially provide significant improvements in the lives of cancer patients. Its operations span various stages of clinical development, with projects targeting a broad range of cancer types. Syndax is especially known for its work on epigenetics and immune-oncology, areas where they seek to unlock new treatment pathways. The main objectives of the company include advancing its clinical programs to commercialization, expanding its pipeline through strategic collaborations and research & development, and ultimately improving patient outcomes in the oncology field.